MedTrace Logo

Relative Bioavailability and Food Effect Study

NCT00827515 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-03-05

No results posted yet for this study

Summary

Initial studies have used a powder in capsule formulation of PH797804. In future studies an immediate release tablet will be used. The purpose of this study is to compare blood levels of PH797804 following an oral dose of the powder in capsule formulation and the tablet formulation. In addition the effect of food blood levels of PH797804 will be investigated

Conditions

Interventions

DRUG

PH797804

Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fasted state

DRUG

PH797804

Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fed state

DRUG

PH797804

Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fasted state

DRUG

PH797804

Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fed state

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-04-30
Completion
2009-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00827515 on ClinicalTrials.gov